This post was written by SmartBrief’s Elizabeth Collins.
The pharmaceutical companies that say they are waiting for the Food and Drug Administration to issue new guidance on how to handle drug promotion through social media are just using the FDA’s guidance delay as an “out,” or an excuse, said Glenn Byrd, MedImmune’s director of regulatory affairs, at the Marcus Evans “Social Media for Pharma” conference in Washington, D.C., on Thursday.
Some in the industry feel that when the FDA finally issues its social media guidance, answers to all their questions will suddenly become clear, he says. He doesn’t think that will be the case. He points to what we already know, however, which should be enough to get companies started.
The FDA will regulate anything a pharmaceutical company does to generate interest in its products, and Byrd reminded the audience that the FDA has already made clear what its expectations are in regards to advertisements and promotions. “There’s already guidance